Mitchel L. Zoler, PhD
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
![1]()
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
May 18, 2021
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.
![1]()
News
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
May 15, 2021
When treating patients with no history of heart failure within days of an acute myocardial infarction, sacubitril/valsartan showed safety but no clear superiority to ramipril.
![1]()
News
Hypertension worsened by commonly used prescription meds
May 6, 2021
Close to 20% of U.S. adults with hypertension are on a prescription drug, such as NSAIDs, known to raise blood pressure, creating an opportunity for drug substitution.
![1]()
News
Half of patients in hospital for COVID-19 get acute kidney injury
April 27, 2021
It’s bad news when hospitalized COVID-19 patients develop acute kidney injury, which can prove fatal or can lead to the development or worsening of CKD.
![1]()
News
Thirteen percent of patients with type 2 diabetes have major ECG abnormalities
March 2, 2021
ECGs from more than 8,000 Dutch patients with type 2 diabetes, most without known cardiovascular disease, show that major abnormalities are not unusual.
![1]()
News
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.
![1]()
News
Empagliflozin favorably reshaped left ventricles in HFrEF patients
November 15, 2020
Results from two separate randomized studies showed empagliflozin treatment of patients with HFrEF produced significant heart remodeling.
![1]()
News
GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit
November 13, 2020
Omecamtiv mecarbil safely met its primary efficacy endpoint in patients with heart failure with reduced ejection fraction in GALACTIC-HF, but with a modest effect.
News
New eGFR equation ‘less biased’ by age, kidney function; some disagree
November 10, 2020
The European Kidney Function Consortium equation surpasses existing equations by "resulting in generally lower bias across the spectrum of age and kidney function," according to its developers.
